Vanguard Group Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Vanguard Group Inc. boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,347,449 shares of the company’s stock after purchasing an additional 155,579 shares during the quarter. Vanguard Group Inc. owned about 8.69% of Intellia Therapeutics worth $254,514,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Avidity Partners Management LP grew its stake in shares of Intellia Therapeutics by 18.0% during the 4th quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock valued at $13,642,000 after buying an additional 68,334 shares during the period. Charles Schwab Investment Management Inc. grew its position in Intellia Therapeutics by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after acquiring an additional 18,987 shares during the period. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after acquiring an additional 1,463,820 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Intellia Therapeutics by 5.9% in the 3rd quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after purchasing an additional 14,863 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in shares of Intellia Therapeutics by 13.3% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock valued at $1,104,000 after purchasing an additional 4,255 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Down 3.5 %

Shares of NASDAQ NTLA opened at $22.38 on Monday. Intellia Therapeutics, Inc. has a 52-week low of $19.37 and a 52-week high of $46.50. The stock has a market capitalization of $2.16 billion, a P/E ratio of -4.18 and a beta of 1.84. The stock’s 50 day moving average price is $23.76 and its two-hundred day moving average price is $26.28.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The firm had revenue of $28.94 million for the quarter, compared to analysts’ expectations of $15.60 million. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -4.98 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday. BMO Capital Markets raised their target price on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.00.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.